TregCell Radar

[Dr. Dominic Ng @DrDominicNg]

I'm a neuroscientist.

Here are 4 surprising things that protect your brain from premature aging:
1. Brushing your teeth
Chronic gum disease is linked to higher risk of dementia and faster progression.

[TregCell Radar @TregCellRadar]

@Gantosj New PD1-targeted PD-1-IL2 proteins (IL-2Rα engagement + masked IL-2 outside the tumor) should be far more promising imho.

[TregCell Radar @TregCellRadar]

https://t.co/MhaDki4gSH

[Stephane Boissel @BoisselStephane]

This is very emotional to me. Congrats to Sangamo and my former TxCell team. Forever first! https://t.co/vJ9ThkAzet

[Peptide-based Immunotherapy @LabWalz]

We conducted a phase I #clinicaltrial with CoVac-1, our #peptide-based #COVID19 #vaccine candidate for induction of SARS-CoV-2 T cell immunity. Our observations support the presently ongoing phase II trial for patients with B cell/antibody deficiency. Here’s what we found:

[TregCell Radar @TregCellRadar]

@fitterhappierAJ @AnitaSusmoka Earlier this year, @RoganAGrant raised this possibility that macrophages could support viral replication of sars-cov2.
https://t.co/EQhgiZNjvC

[Rogan Grant @RoganAGrant]

Original paper: https://t.co/AAUfqreBnW

[Leonardo Ferreira @enhancerleo]

Brilliant! #Regulatory #Tcells (#Tregs) expressing #TNFR2 suppress #MultipleSclerosis in a #mouse #model (EAE) #LOCALLY and at the #PEAK of the #disease!!! #Systemic anti #TNF exacerbated disease. @Sorbonne_Univ_ @Inserm @PNASNews #immunologymatters https://t.co/motem6ZNkn

[David Usharauli @3DiMMUNE]

new finding. anti-PD1 reactivates Tregs too in tumors. #cancer #Immunotherapies #Immunology

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies | Nature Immunology https://t.co/geGgCiROGi

[TregCell Radar @TregCellRadar]

PD-L1 – PD-1 interactions limit effector Treg cell populations at homeostasis and during infection https://t.co/31higddUey

[The Science of Parkinson's @ScienceofPD]

COVID vaccine company @moderna_tx & @unmc researchers (@hegendel) report lipid nanoparticles containing granulocyte-macrophage colony-stimulating factor mRNA (Gm-csf mRNA) - to peripherally induce Tregs - offers neuroprotection in models of #Parkinsons
https://t.co/jdvvkVZl29

[TregCell Radar @TregCellRadar]

@fitterhappierAJ @GR67587007 Did you see that Merck discontinues MK-7110, a mab they bought 400M$ last november after promising early results? ☹️
https://t.co/2lm15KbiWh

[Evaluate Pharma @evaluatepharma]

The antiviral pipeline for #Covid19 treatment shrinks, as Merck discontinues MK-7110 and reduces the scope of molnupiravir: https://t.co/DsUkRZIYxf

[TregCell Radar @TregCellRadar]

New agonist MAb resolves chronic inflammation https://t.co/k5dOA0VzNZ

[Monica Gandhi MD, MPH @MonicaGandhi9]

Wanted to drill down a bit more about the importance of the T-cell response to SARS-CoV-2 to give you more reassurance of enduring protection from vaccines (even against variants). Technical article here but CD4/CD8 cells have role in both acute infection https://t.co/e5azau2cg1

[TregCell Radar @TregCellRadar]

@fitterhappierAJ Peptides corresponding to mutated sequences will of course result in T cell escape. However, there are regions that have remained largely invariant to date.

[Alfred Kim @alhkim]

On behalf of the entire #COVaRiPAD team, we are thrilled to announce our preprint reporting humoral responses after BOTH doses of mRNA-based SARS-CoV-2 vax in 133 pts w/ chronic inflammatory diseases (CID) and 53 immunocompetent controls: https://t.co/s6a3J1bKGZ.
1/

[TregCell Radar @TregCellRadar]

@chaminadejp @DeBunKerEtoiles ils poursuivent avec les personnes avec comorbidités. ces projets peuvent aller vite étant donné le fort besoin.

https://t.co/8QyIJTH5a6

[TregCell Radar @TregCellRadar]

@chaminadejp @DeBunKerEtoiles le seul projet du même type (axé 100% cellules T) que je connais est un projet de l’université allemande de Tubinguen (covac-1). Ils sont entrés en clinique en décembre et viennent d’annoncer la safety et l’immunogénicité de leur vaccin (ph1, personnes en bonne santé).

[TregCell Radar @TregCellRadar]

@chaminadejp @DeBunKerEtoiles Oui, ca aurait été une bonne idée. Ose immuno travaille sur un « booster » destiné à induire une réponse T plus puissante et plus large à destination, entre autres, des personnes immunodéprimées. Démarrage des essais cliniques imminent. https://t.co/tdJNng9p4I

[TregCell Radar @TregCellRadar]

@chaminadejp @DeBunKerEtoiles ca n’est malheureusement pas inhabituel. 30% des vaccinés de plus de 80 ans dans cette petite étude: https://t.co/VQIZ2M6MW2

[TregCell Radar @TregCellRadar]

@ArditiMd @fitterhappierAJ @xolaniboy @MLevitt_NP2013 @MonicaGandhi9 Another 2 cases report :

https://t.co/C3H2RCpxbg